2025 ESMO Asia・E情报 | 中国“胃”道力量震撼狮城——53项研究全线出击
2025-12-04


图片


  //  

2025年欧洲肿瘤内科学会亚洲年会(ESMO Asia 2025)将于12月5日至7日在新加坡隆重举行。ESMO亚洲年会是亚太地区肿瘤学领域的重要盛会,云集了亚太地区以及全球的肿瘤学专家学者,聚焦于引领亚太乃至全球肿瘤诊疗变革的突破性研究。


目前,ESMO Asia官网已正式公布入选研究标题信息,胃食管癌领域共53项中国研究入选优选论文会议(Proffered paper session)、迷你口头报告(Mini oral session)和壁报展示(Poster)环节,医脉通整理如下,带您先睹为快!




Proffered paper session





摘要号:271O

研究名称(英文):Final Analysis and Biomarker Evaluation of JUPITER-06: A Phase 3 Trial of Toripalimab Plus Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

研究名称(中文):JUPITER-06研究的最终分析与生物标志物评估:特瑞普利单抗联合化疗治疗晚期或转移性食管鳞状细胞癌的III期临床试验

讲者:王峰 | 中山大学肿瘤防治中心




Mini oral session





摘要号: LBA5

研究名称(英文):Updated results from a phase 1 study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), in combination with toripalimab and chemotherapy as the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA)

研究名称(中文):JS107(一种靶向Claudin 18.2的抗体-药物偶联物)联合特瑞普利单抗和化疗作为晚期胃癌或胃食管交界腺癌一线治疗的I期研究更新结果

讲者:阮丹云 | 中山大学肿瘤防治中心


摘要号:277MO

研究名称(英文):Efficacy and safety of adebrelimab combined with S-1 plus oxaliplatin in neoadjuvant therapy for locally advanced gastric adenocarcinoma

研究名称(中文):阿得贝利单抗联合S-1加奥沙利铂用于局部晚期胃癌新辅助治疗的疗效与安全性

讲者:杨建军 | 空军军医大学西京医院




Poster





摘要号:296P

研究名称(英文):The Omitted Prognostic Power of Pathological Lymph Node Regression After Neoadjuvant Therapy in Patients with Gastric Cancer: From Multicenter Perspective

研究名称(中文):被忽视的新辅助治疗后病理淋巴结退缩在胃癌患者中的预后价值:一项多中心研究视角

讲者:Qing Zhong | 福州


摘要号:298P

研究名称(英文):SHR-1701 Plus CAPOX in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and PD-L1 Combined Positive Score ≥1: A Post-hoc Analysis of a Phase III Study

研究名称(中文):SHR-1701联合CAPOX治疗PD-L1联合阳性评分(CPS)≥1的晚期胃癌或胃食管交界腺癌患者:一项 III 期研究的事后分析

讲者:彭智 | 北京大学肿瘤医院


摘要号:299P

研究名称(英文):First-line Osemitamab plus Nivolumab and CAPOX for Advanced G/GEJ Cancer (TranStar102) – Updated Efficacy Analysis of Cohort G by CLDN18.2 and PD-L1 Expression from a Phase I/II Study

研究名称(中文):一线Osemitamab联合纳武利尤单抗及CAPOX方案用于晚期胃癌/胃食管交界癌(TranStar102 研究)——基于CLDN18.2与PD-L1表达的 I/II 期队列G更新疗效分析

讲者:Dan Liu | 北京


摘要号:300P

研究名称(英文):Zolbetuximab plus mFOLFOX6/CAPOX as first-line (1L) treatment in patients with claudin 18 isoform 2 positive (CLDN18.2+) metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma with peritoneal metastases: A post hoc analysis of SPOTLIGHT and GLOW

研究名称(中文):Zolbetuximab联合mFOLFOX6/CAPOX作为Claudin18.2阳性伴腹膜转移的转移性胃癌或胃食管交界腺癌一线治疗:SPOTLIGHT与GLOW研究事后分析

讲者:徐瑞华 | 中山大学肿瘤防治中心


摘要号:301P

研究名称(英文):Cadonilimab (Cado) plus oxaliplatin and tegafur-gimeracil-oteracil potassium (SOX) in resectable gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: A phase II study (Compassion-25)

研究名称(中文):Cadonilimab(Cado)联合奥沙利铂及替吉奥(SOX)方案用于可切除胃癌和胃食管交界腺癌:一项 II 期 Compassion-25 研究

讲者:Bin Li | 天津


摘要号:302P

研究名称(英文):Spatial single-cell multi-omics characterization of the tumor microenvironment heterogeneity by HER-2 expression status in gastric cancer

研究名称(中文):胃癌中HER-2表达状态的空间单细胞多组学解析:肿瘤微环境异质性全景

讲者:彭浩欣 | 北京大学肿瘤医院


摘要号:304P

研究名称(英文):Pyrotinib combined with dalpiciclib in the treatment of refractory advanced HER2 positive gastric cancer or solid tumors: safety and efficacy results from a phase Id trial

研究名称(中文):吡咯替尼联合达尔西利治疗难治性晚期HER2阳性胃癌或实体瘤的Ib期安全性和疗效结果

讲者:Jifang Gong | 北京


摘要号:305P

研究名称(英文):Safety and Efficacy of Endoscopic Resection Followed by Adjuvant Chemoradiotherapy (ERACT) for Organ Preservation in Early-Stage Esophageal Squamous Cell Carcinoma with High-Risk Features: A Prospective, Multicenter, Phase II Clinical trial

研究名称(中文):高风险早期食管鳞癌内镜切除后辅助放化疗(ERACT)保留器官的前瞻性多中心II期临床试验:安全性与疗效

讲者:Jianrui Ji | 北京


摘要号:306P

研究名称(英文):Pre-Treatment BMI–Based Prognostic Stratification of Cachexia in Gastric Adenocarcinoma Undergoing Neoadjuvant Chemotherapy: A Combined Body Composition and Tumor Microenvironment Analysis

研究名称(中文):基于治疗前BMI的胃腺癌恶病质预后分层研究:新辅助化疗背景下体成分与肿瘤微环境联合分析

讲者:Chenyu Tian | 北京


摘要号:307P

研究名称(英文):Comprehensive Genomic Profiling Identifies Targetable Alterations in Advanced Esophageal Squamous Cell Carcinoma: A Single-Center Study from Taiwan

研究名称(中文):台湾单中心研究:全面基因组测序发现晚期食管鳞癌可靶向基因组变异

讲者:Cheng-Lun Lai | 台湾


摘要号:308P

研究名称(英文):Association of Comprehensive Inflammatory-Metabolic Status and Perioperative Outcomes in Gastric Cancer: Insights from Four Randomized Controlled Trials

研究名称(中文):胃癌全身炎症-代谢状态与围手术期结局的关联:四项随机对照试验汇总分析

讲者:Shangguan Zhixin | 福州


摘要号:309P

研究名称(英文):Clinical outcomes and immune contexture in SMARCA4-deficient gastric cancer patients

研究名称(中文):SMARCA4缺失型胃癌患者的临床结局与免疫微环境特征

讲者:Hongyong He | 上海


摘要号:310P

研究名称(英文):Real-World Effectiveness and Adverse Effects of Nivolumab Plus Chemotherapy in Elderly Patients With Metastatic Gastric Cancer: A TriNetX Analysis

研究名称(中文):真实世界TriNetX数据库分析:纳武利尤单抗联合化疗治疗老年转移性胃癌的有效性与不良反应

讲者:Yu-Hsuan Shih | 台湾


摘要号:311P

研究名称(英文):Treatment Patterns, HER2 Testing Practices, and Clinical Outcomes in HER2-Positive Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (REHEARSAL): A Multicenter Retrospective Real-World Study in China

研究名称(中文):REHEARSAL研究:中国多中心回顾性真实世界研究解析HER2阳性局部晚期不可切除或转移性胃癌/胃食管交界癌的治疗模式、HER2检测实践及临床结局

讲者:Yakun Wang | 北京


摘要号:312P

研究名称(英文):Efficacy and safety of HLX43 (an anti-PD-L1 ADC) in recurrent/metastatic esophageal squamous cell carcinoma (ESCC): a multicentre, randomised phase 2 study

研究名称(中文):HLX43(抗PD-L1 ADC)治疗复发/转移性食管鳞癌的疗效与安全性:多中心随机II期研究

讲者:Linlin Wang | 济南


摘要号:313P

研究名称(英文):Characteristics, treatment patterns, and outcomes with first-line nivolumab plus chemotherapy vs chemotherapy in CheckMate 649 patients by regions

研究名称(中文):CheckMate 649研究按地区分析:纳武利尤单抗联合化疗 vs 单纯化疗一线治疗的患者特征、治疗模式及结局

讲者:沈琳 | 北京大学肿瘤医院


摘要号:314P

研究名称(英文):Updated outcome and ctDNA Profiling in Advanced HER2+ Gastric Cancer Patients Treated with DOS plus Serplulimab and Trastuzumab: A Phase II Multicenter Trial

研究名称(中文):DOS方案联合斯鲁利单抗和曲妥珠单抗治疗晚期HER2+胃癌的II期多中心研究:最新结局与ctDNA分析

讲者:刘天舒 | 复旦大学附属中山医院


摘要号:315P

研究名称(英文):Identification of Potential Immune Biomarkers associating to Clinical Benefit from Intensive Chemotherapy Combined with Serplulimab and Trastuzumab in Advanced HER2+ Gastric Cancer: A Post-hoc Analysis of the ASTRUM Study

研究名称(中文):ASTRUM研究事后分析:晚期HER2+胃癌强化化疗联合斯鲁利单抗及曲妥珠单抗临床获益相关潜在免疫生物标志物鉴定

讲者:刘天舒 | 复旦大学附属中山医院


摘要号:318P

研究名称(英文):Real-World Evidence on Adjuvant S-1 Plus Docetaxel Therapy in Stage III Gastric Cancer

研究名称(中文):Ⅲ期胃癌术后S-1联合多西他赛辅助治疗的真实世界证据

讲者:KUAN-CHANG LAI | 台湾


摘要号:320P

研究名称(英文):When Adipose Meets Inflammation: A Novel Paradigm for Prognostic Assessment in Locally Advanced Gastric Cancer Undergoing Neoadjuvant Chemotherapy

研究名称(中文):当脂肪遇上炎症:局部进展期胃癌新辅助化疗预后评估的新范式

讲者:Ling-kang Zhang | 福州


摘要号:321P

研究名称(英文):Real-world effectiveness of adjuvant nivolumab in Chinese patients with esophageal cancer/gastroesophageal junction cancer: a retrospective observational study

研究名称(中文):中国食管癌/胃食管交界癌术后辅助纳武利尤单抗真实世界有效性回顾性观察研究

讲者:李志刚 | 上海市胸科医院


摘要号:326P

研究名称(英文):Real-world PD-L1 prevalence and first-line (1L) treatment patterns by PD-L1 expression in advanced gastric /gastroesophageal junctional cancer (GC/GEJC) in China: The REPRESENT study

研究名称(中文):中国晚期胃癌/胃食管结合部癌PD-L1真实世界表达率及一线治疗模式:REPRESENT研究

讲者:Fan Chen | 广州


摘要号:329P

研究名称(英文):Exploring Concordance Between Clinical and Pathological Staging in Resectable Gastric Cancer in Taiwan

研究名称(中文):台湾可切除胃癌临床-病理分期一致性探索

讲者:Chieh-Ying Chang | 台湾


摘要号:330P

研究名称(英文):POSTN-driven lipid metabolism dysregulation mediates immunotherapy resistance via the integrin ITGB1–PPAR axis and foam-like macrophage polarization in gastric cancer

研究名称(中文):胃癌中POSTN驱动脂质代谢紊乱通过整合素ITGB1-PPAR轴及泡沫样巨噬细胞极化介导免疫治疗耐药

讲者:Qin Ding | 上海


摘要号:332P

研究名称(英文):Neoadjuvant FLOT With or Without Durvalumab Followed by S-1–Based Adjuvant Therapy for Gastric Cancer: Real-World Evidence From Asia

研究名称(中文):胃癌新辅助FLOT±度伐利尤单抗后S-1辅助化疗:亚洲真实世界证据

讲者:Yi Chieh Chen | 台湾


摘要号:333P

研究名称(英文):External validation of the predictive value of combined prealbumin and lymphocyte (Co-PaL) score for prognosis of stage II/III gastric cancer following curative resection

研究名称(中文):前白蛋白-淋巴细胞联合(Co-PaL)评分对Ⅱ/Ⅲ期胃癌根治术后预后预测价值的外部验证

讲者:Hua Xiao | 长沙


摘要号:339P

研究名称(英文):High Pathological Response and Excellent Surgical Safety with Neoadjuvant Radiotherapy plus SOX and Sintilimab in Locally Advanced Gastroesophageal Junction Adenocarcinoma: A Prospective Single-Center Study

研究名称(中文):新辅助放疗联合SOX及信迪利单抗治疗局部晚期胃食管交界腺癌:病理反应高、手术安全性佳的单中心前瞻性研究

讲者:Hongli Liu | 武汉


摘要号:340P

研究名称(英文):Reduced-Intensity CRT Plus PD-1 Inhibitor for Elderly ESCC: A Retrospective Cohort

研究名称(中文):低强度放化疗联合PD-1抑制剂治疗老年食管鳞癌:回顾性队列研究

讲者:Han Zhang | 重庆


摘要号:341P

研究名称(英文):A Meta-Analysis of Perioperative Immunotherapy Modalities in Patients with dMMR/MSI-H Gastric and Gastroesophageal Junction Adenocarcinoma

研究名称(中文):dMMR/MSI-H胃癌及胃食管交界腺癌围手术期免疫治疗方式的荟萃分析

讲者:Hongfei Yan | 沈阳


摘要号:344P

研究名称(英文):Estimating the Burden of Gastric Cancer in First-Degree Relatives of Gastric Cancer Patients in Hong Kong

研究名称(中文):香港胃癌患者一级亲属的胃癌疾病负担评估

讲者:Gin Wai G. Kwok | 香港


摘要号:423eP

研究名称(英文):Real-world experience of FLOT regimen among patients with adenoacarcinoma of gastric (GC) and oesophagogastric junction (OGJ)

研究名称(中文):FLOT方案在胃腺癌及食管胃结合部腺癌患者中的真实世界用药经验

讲者:Winnie Yeo  | 香港


摘要号:425eP

研究名称(英文):Neoadjuvant chemoradiotherapy (nCRT) followed by sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Updated results of a single-arm, open-label phase Ib trial (CRIS)

研究名称(中文):可切除食管鳞癌新辅助放化疗序贯替雷利珠单抗的单臂、开放标签Ib期试验(CRIS研究)更新结果

讲者:Youhua Jiang | 杭州


摘要号:428eP

研究名称(英文):Dynamic risk from routine blood tests: an artificial intelligence two-point vector score for gastric cancer screening

研究名称(中文):基于常规血液检测的动态风险:用于胃癌筛查的人工智能两点向量评分

讲者:Minji Seo | 香港


摘要号:441eP

研究名称(英文):CXCL13 promoting the secretion of Galectin-9 from tumor-associated macrophages to mediate gastric cancer immune evasion through Interferon signaling pathway

研究名称(中文):CXCL13 通过干扰素信号通路促进肿瘤相关巨噬细胞分泌 Galectin-9 介导胃癌免疫逃逸

讲者:Yichou Wei  | 上海


摘要号:442eP

研究名称(英文):Preventing Futile gastrectomy after neoadjuvant chemotherapy: A preoperative risk-based evaluation system for gastric cancer

研究名称(中文):避免无效胃切除术:胃癌新辅助化疗后的术前风险评价体系

讲者:Dong Wu | 福州


摘要号:443eP

研究名称(英文):Analysis of Multimodal Features and Prognostic Risk in Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy Based on Machine Learning Algorithms: A Multicenter Study

研究名称(中文):基于机器学习算法的局部进展期胃癌新辅助化疗后多模态特征与预后风险分析:一项多中心研究

讲者:Li Liu | 福州


摘要号:450eP

研究名称(英文):Establishing Surgical Quality Metrics for Gastrectomy in the Minimally Invasive Era: A Benchmark Analysis of 24 High-Volume Centers

研究名称(中文):微创时代胃切除术手术质量标准的建立:24家高容量中心的基准分析

讲者:Dong Wu | 福州


摘要号:451eP

研究名称(英文):Dynamic Postoperative Prognosis and Follow-up Optimization for Gastric Cancer Patients After Neoadjuvant Therapy: A Multicenter Real-World Study

研究名称(中文):新辅助治疗后胃癌患者术后动态预后评估与随访优化:多中心真实世界研究

讲者:Zhi-Quan Zhang | 福州


摘要号:452eP

研究名称(英文):Phase II study of Adebrelimab combined with Apatinib and nab-Paclitaxel as second-line therapy in patients with advanced gastric cancer previously treated with immunotherapy

研究名称(中文):阿得贝利单抗联合阿帕替尼及白蛋白结合型紫杉醇二线治疗既往接受过免疫治疗的晚期胃癌的II期研究

讲者:Guanghai Dai | 北京


摘要号:464eP

研究名称(英文):Phase 2 trial of adjuvant sintilimab in lymph node-positive esophageal squamous cell carcinoma (ESCC) after radical surgery without neoadjuvant treatment

研究名称(中文):根治术后淋巴结阳性食管鳞癌患者辅助信迪利单抗治疗的2期试验(无新辅助治疗背景)

讲者:Changchun Wang | 杭州


摘要号:469eP

研究名称(英文):Clinical Efficacy Analysis of Neoadjuvant Chemoimmunotherapy Combined with Robot-Assisted Ivor-Lewis Esophagectomy for Adenocarcinoma of the Esophagogastric Junction

研究名称(中文):新辅助化学免疫治疗联合机器人辅助Ivor-Lewis食管切除术治疗食管胃交界腺癌的临床疗效分析

讲者:Xiaofeng Duan | 天津


摘要号:470eP

研究名称(英文):Multimodal imaging–clinical modeling to predict pathologic response after neoadjuvant chemoimmunotherapy for resectable ESCC

研究名称(中文):可切除食管鳞癌新辅助化学免疫治疗后病理缓解的多模态影像-临床预测模型

讲者:Xue He | 长沙


摘要号:471eP

研究名称(英文):Short-course Hypofractionated Radiotherapy in Combination with Raltitrexed and Tislelizumab in Patients with Region-relapsed or Progressive Esophageal Squamous Cell Carcinoma: Medium-term analysis

研究名称(中文):短程大剂量分割放疗联合雷替曲塞与替雷利珠单抗治疗区域复发/进展食管鳞癌的中期分析

讲者:Yuan He | 合肥


摘要号:473TiP

研究名称(英文):A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients with HER2 Expressing Gastric Cancer (CORNERSTONE-003, NCT05771584)

研究名称(中文):治疗性癌症疫苗(AST-301,pNGVL3-hICD)用于HER2表达胃癌患者的安全性与免疫疗效评估Ⅱ期研究(CORNERSTONE-003,NCT05771584)

讲者:Shao-Ciao Luo | 台湾


摘要号:478eTiP

研究名称(英文):IBI343 Combined with Sintilimab and SOX as First-Line Therapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma (G/GEJAC)

研究名称(中文):IBI343联合信迪利单抗及SOX方案一线治疗CLDN18.2阳性、HER2阴性局部晚期不可切除或转移性胃/胃食管交界腺癌(G/GEJAC)

讲者:Min Shi | 上海


摘要号:480eTiP

研究名称(英文):YOUNG-NEOS: Phase II study of neoadjuvant nab-paclitaxel, oxaliplatin s-1, and sintilimab for resectable early-onset GC/GEJC patients

研究名称(中文):YOUNG-NEOS:可切除早发性胃/胃食管交界腺癌新辅助白蛋白紫杉醇+奥沙利铂+S-1+信迪利单抗的Ⅱ期研究

讲者:Xuesong Zhao | 北京


摘要号:482eTiP

研究名称(英文):Neoadjuvant Adebrelimab plus SOX and Nab-paclitaxel in Resectable Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: A Multicentre, Single-arm, Prospective Phase II Trial

研究名称(中文):阿得贝利单抗联合SOX及白蛋白紫杉醇新辅助治疗可切除局部晚期胃/胃食管交界腺癌:多中心、单臂、前瞻性Ⅱ期试验

讲者:Pin Liang | 大连


摘要号:483eTiP

研究名称(英文):Adebrelimab Combined with Celecoxib and Chemotherapy as First-Line Treatment for PD-L1-Positive and HER2-Negative Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Exploratory Clinical Trial

研究名称(中文):阿得贝利单抗联合塞来昔布及化疗一线治疗PD-L1阳性、HER2阴性局部晚期胃/胃食管交界腺癌:单臂探索性临床试验

讲者:Zhang Bin | 大连


摘要号:484eTiP

研究名称(英文):Tislelizumab Combined with SOX for Neoadjuvant Long-Course Treatment of Locally Advanced GC/GEJ:A Phase II trial

研究名称(中文):替雷利珠单抗联合SOX方案新辅助长程治疗局部晚期胃/胃食管交界腺癌:Ⅱ期试验

讲者:Guoliang Zheng | 沈阳


摘要号:486eTiP

研究名称(英文):Interim Results and ctDNA Biomarker Analysis from the Phase III SCIENCE Trial: Neoadjuvant Chemotherapy or Chemoradiotherapy With/Without Sintilimab for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

研究名称(中文):III期SCIENCE研究中期结果及ctDNA生物标志物分析:可切除局部晚期食管鳞癌新辅助化疗或放化疗±信迪利单抗

讲者:Xuefeng Leng | 成都



来源:ESMO Asia官网

整理:Aurora

排版:Aurora

执行:Aurora






医脉通是专业的在线医生平台,“感知世界医学脉搏,助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品,全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。


本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容,不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的,本平台不承担相关责任。本平台对发布的内容,并不代表同意其描述和观点。若涉及版权问题,烦请权利人与我们联系,我们将尽快处理。


图片

(本网站所有内容,凡注明来源为“医脉通”,版权均归医脉通所有,未经授权,任何媒体、网站或个人不得转载,否则将追究法律责任,授权转载时须注明“来源:医脉通”。本网注明来源为其他媒体的内容为转载,转载仅作观点分享,版权归原作者所有,如有侵犯版权,请及时联系我们。)

0
收藏 分享